Top 5 Takeaways Increased Protection with Boosters: Additional primary or booster COVID-19 vaccine doses significantly enhance protection against the Omicron variant in nursing home residents, showing a relative vaccine effectiveness

Top 5 Takeaways New Vaccine Option: JYNNEOS, a replication-deficient Vaccinia virus vaccine licensed in 2019, is now recommended by ACIP for preexposure prophylaxis against orthopoxviruses, offering an alternative to ACAM2000.

Top 5 Takeaways New Vaccine Approval: The FDA has approved the Pfizer Pentavalent Meningococcal Vaccine (MenACWY-TT/MenB-FHbp, branded as Penbraya) for individuals aged 10–25 years to protect against serogroups A, B,

Top 5 Takeaways Initial Disparities in Vaccination Coverage: Early in the vaccination campaign, Asian and non-Hispanic White adults had the highest COVID-19 vaccination coverage, while coverage was lower among Hispanic,

Top 5 Takeaways Low incidence of sudden cardiac death post-vaccination: Among 1,292 deaths of Oregon residents aged 16–30 during the study period, only three sudden deaths occurred within 100 days

Top 5 Takeaways Significant Increase in Vaccine Supply: From 2021 to 2023, COVID-19 vaccine doses received in the African Region increased from 321 million to 860 million, with 646 million

Top 5 Takeaways Novel OPV2 Shows Genetic Stability: Global genomic surveillance confirms the genetic stability of the novel oral poliovirus vaccine type 2 (nOPV2), maintaining the primary attenuating site’s integrity

Top 5 Takeaways Significant Contribution by FRPP: The Federal Retail Pharmacy Program (FRPP) partners administered 67.7% of the 59.8 million COVID-19 bivalent vaccine doses in the U.S. during the study

Top 5 Takeaways FDA Approvals and ACIP Recommendations: The FDA issued Emergency Use Authorizations for the Moderna and Pfizer-BioNTech COVID-19 vaccines for children aged 6 months–5 years and 6 months–4

Top 5 Takeaways Reduced Reactions Post-Booster: Immunocompromised individuals aged ≥12 years reported fewer local and systemic reactions after the fourth dose (mRNA booster) compared to after the third dose of